Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy Claude Enterprise across its global operations.

MEKanistic Therapeutics has received clearance from the U.S. Food and Drug Administration for its Investigational New Drug (IND) application for MTX-531, allowing the company to begin a Phase 1 clinical trial in advanced solid tumours.

Bio-Thera Solutions and Accord BioPharma have announced that the US Food and Drug Administration (FDA) has approved IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), the first biosimilars to Simponi® and Simponi Aria® in the United States.

INmune Bio Inc. has announced that the U.S. Food and Drug Administration has granted Fast Track designation to XPro™ (pegipanermin) for the treatment of early Alzheimer’s disease.

Elabscience has launched a self-developed PolyHRP-Streptavidin conjugate designed to improve the sensitivity of enzyme-linked immunosorbent assay (ELISA) testing for low-abundance biomarker detection.

Samsung Bioepis and ATLATL have signed a Memorandum of Understanding to drive early-stage biotechnology innovation across the Asia-Pacific region, focusing on R&D collaboration.

Acadia Pharmaceuticals will disclose first quarter 2026 financial results after market close today, followed by a management-hosted conference call at 4:30 p.m. ET.

Samsung Bioepis and ATLATL have signed a Memorandum of Understanding to drive early-stage biotech innovation across the Asia-Pacific region through enhanced collaboration.

India's Sun Pharmaceuticals is acquiring Organon & Co. for $11.75 billion to enhance its women's health portfolio, biosimilars, and global reach from its Mumbai base.[2]

The U.S. government has enacted measures to reduce reliance on imported pharmaceuticals and active pharmaceutical ingredients, citing threats to national security and supply chain vulnerabilities.